Published in Diabetes on August 03, 2009
Mechanisms for insulin resistance: common threads and missing links. Cell (2012) 6.85
Lipid-induced insulin resistance: unravelling the mechanism. Lancet (2010) 4.88
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology (2014) 4.01
Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology (2010) 3.52
A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem (2009) 3.41
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 2.92
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest (2012) 2.62
The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol (2010) 2.50
Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology (2010) 2.47
Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology (2010) 2.09
Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat Med (2012) 1.87
Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology (2014) 1.81
Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res (2010) 1.75
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients (2013) 1.73
Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab (2012) 1.71
A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology (2010) 1.71
NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver (2012) 1.70
Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab (2012) 1.64
The genetics of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.55
Genetic determinants of hepatic steatosis in man. J Lipid Res (2011) 1.52
Relationships of circulating sex hormone-binding globulin with metabolic traits in humans. Diabetes (2010) 1.43
The metabolically benign and malignant fatty liver. Diabetes (2011) 1.39
Toward a unifying hypothesis of metabolic syndrome. Pediatrics (2012) 1.36
Dissociating fatty liver and diabetes. Trends Endocrinol Metab (2012) 1.29
Mammalian triacylglycerol metabolism: synthesis, lipolysis, and signaling. Chem Rev (2011) 1.28
Liver fat content determined by magnetic resonance imaging and spectroscopy. World J Gastroenterol (2010) 1.25
The role of hepatokines in metabolism. Nat Rev Endocrinol (2013) 1.21
Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet (2010) 1.20
The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS One (2011) 1.18
Effects of PNPLA3 on liver fat and metabolic profile in Hispanic children and adolescents. Diabetes (2010) 1.17
Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia. Diabetologia (2011) 1.17
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des (2013) 1.16
Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats. Hepatology (2013) 1.16
The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. Annu Rev Nutr (2010) 1.15
Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World J Gastroenterol (2012) 1.13
Genome-wide association analysis of soluble ICAM-1 concentration reveals novel associations at the NFKBIK, PNPLA3, RELA, and SH2B3 loci. PLoS Genet (2011) 1.10
Liver and diabetes. A vicious circle. Hepatol Res (2013) 1.10
A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Hum Genet (2012) 1.08
Type 2 diabetes: etiology and reversibility. Diabetes Care (2013) 1.06
Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol (2014) 1.02
Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS One (2012) 1.02
The association between hepatic fat content and liver injury in obese children and adolescents: effects of ethnicity, insulin resistance, and common gene variants. Diabetes Care (2012) 1.00
Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population. PLoS One (2012) 1.00
PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease. World J Gastroenterol (2012) 0.97
Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease. Hepatology (2010) 0.96
PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease. Am J Gastroenterol (2015) 0.93
Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int (2015) 0.93
The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol (2012) 0.91
Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci (2014) 0.91
Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis. Sci Rep (2015) 0.90
Association of PNPLA3 SNP rs738409 with liver density in African Americans with type 2 diabetes mellitus. Diabetes Metab (2011) 0.88
Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care (2013) 0.88
Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. Int J Mol Sci (2016) 0.86
Identification of combined genetic determinants of liver stiffness within the SREBP1c-PNPLA3 pathway. Int J Mol Sci (2013) 0.85
Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea. Dig Dis Sci (2014) 0.84
Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World J Gastroenterol (2012) 0.84
PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Med Genet (2012) 0.84
Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Obesity (Silver Spring) (2013) 0.84
Endoplasmic reticulum proteostasis in hepatic steatosis. Nat Rev Endocrinol (2016) 0.82
Non-alcoholic fatty liver disease and diabetes. Metabolism (2016) 0.82
Genome-wide analysis of hepatic lipid content in extreme obesity. Acta Diabetol (2014) 0.82
Sexually dimorphic genome-wide binding of retinoid X receptor alpha (RXRα) determines male-female differences in the expression of hepatic lipid processing genes in mice. PLoS One (2013) 0.82
The PNPLA3 rs738409 G-allele associates with reduced fasting serum triglyceride and serum cholesterol in Danes with impaired glucose regulation. PLoS One (2012) 0.81
PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis. World J Gastroenterol (2015) 0.81
Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review. Int J Mol Sci (2016) 0.81
The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid Res (2014) 0.80
Implication of hepatokines in metabolic disorders and cardiovascular diseases. BBA Clin (2016) 0.77
PNPLA3 as a Genetic Determinant of Risk for and Severity of Non-alcoholic Fatty Liver Disease Spectrum. J Clin Transl Hepatol (2016) 0.77
Intrahepatic lipid, not visceral or muscle fat, is correlated with insulin resistance in older, female rhesus macaques. Obesity (Silver Spring) (2013) 0.77
Novel phenotypes of prediabetes? Diabetologia (2016) 0.76
Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol (2016) 0.76
The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background. Gastroenterol Res Pract (2016) 0.76
Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World J Hepatol (2015) 0.76
Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection-Liver: The "Musketeer" in the Spotlight. Int J Mol Sci (2016) 0.76
Serum TAG analysis differentiates between genetic and obesity-associated NAFLD. Diabetes (2014) 0.75
Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease. Semin Liver Dis (2015) 0.75
Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART). PLoS One (2017) 0.75
Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Dig Dis Sci (2016) 0.75
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care (1997) 49.11
Inflammation and metabolic disorders. Nature (2006) 33.33
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care (1999) 26.39
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science (2004) 19.08
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Inflammation and insulin resistance. J Clin Invest (2006) 18.76
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab (2004) 8.36
Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem (2004) 5.80
Identification and characterization of metabolically benign obesity in humans. Arch Intern Med (2008) 5.74
Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes (2006) 4.95
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology (2005) 4.86
Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet (2008) 4.69
Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab (2007) 4.51
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care (2007) 4.42
Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes (1995) 4.33
Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest (2007) 3.88
Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol (2007) 3.83
Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med (2007) 3.54
Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology (2003) 3.42
Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes (2005) 3.36
Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol (2008) 3.16
Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care (2006) 2.99
Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins. J Biol Chem (2001) 2.96
Fetuin-A and incident diabetes mellitus in older persons. JAMA (2008) 2.92
Causes and metabolic consequences of Fatty liver. Endocr Rev (2008) 2.84
Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2006) 2.58
Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. J Lipid Res (2005) 2.56
Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes (2006) 2.50
Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes (2008) 2.41
Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab (2006) 2.31
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology (2005) 2.25
Characterization of the human patatin-like phospholipase family. J Lipid Res (2006) 2.21
Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation (2008) 2.08
Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One (2008) 2.02
Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology (2006) 1.97
Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell (1989) 1.96
Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care (2007) 1.90
Standardized assessment of whole body adipose tissue topography by MRI. J Magn Reson Imaging (2005) 1.85
Adipocyte triglyceride lipase expression in human obesity. Am J Physiol Endocrinol Metab (2007) 1.69
Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia (2005) 1.64
Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care (2006) 1.39
The enzymes of neutral lipid synthesis. J Biol Chem (2001) 1.39
Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity. Eur J Endocrinol (2008) 1.31
Variation in the adiponutrin gene influences its expression and associates with obesity. Diabetes (2006) 1.22
The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans. Clin Sci (Lond) (2009) 1.08
Fatty liver is independently associated with alterations in circulating HDL2 and HDL3 subfractions. Diabetes Care (2007) 1.01
Intrahepatic lipids are predicted by visceral adipose tissue mass in healthy subjects. Diabetes Care (2004) 1.00
Nonsynonymous variants and fatty liver disease. Nat Genet (2008) 0.83
Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg (2012) 19.78
Identification and characterization of metabolically benign obesity in humans. Arch Intern Med (2008) 5.74
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol (2009) 4.38
An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care (2007) 4.14
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med (2003) 4.11
Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med (2011) 3.94
Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care (2006) 2.99
High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes (2002) 2.98
Causes and metabolic consequences of Fatty liver. Endocr Rev (2008) 2.84
A new endoscopic over-the-scope clip system for treatment of lesions and bleeding in the GI tract: first clinical experiences. Gastrointest Endosc (2007) 2.72
Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes (2003) 2.71
Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes (2012) 2.62
Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol (2006) 2.44
Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol (2009) 2.43
Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes (2008) 2.41
Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? Am J Physiol Endocrinol Metab (2008) 2.32
Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care (2005) 2.30
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer (2009) 2.26
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res (2006) 2.26
Polymorphisms within novel risk loci for type 2 diabetes determine beta-cell function. PLoS One (2007) 2.16
Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappaB. J Biol Chem (2004) 2.12
Functional importance of laparoscopic sleeve gastrectomy for the lower esophageal sphincter in patients with morbid obesity. Obes Surg (2012) 2.11
Interaction effect between common polymorphisms in PPARgamma2 (Pro12Ala) and insulin receptor substrate 1 (Gly972Arg) on insulin sensitivity. J Mol Med (Berl) (2001) 2.11
Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation (2008) 2.08
Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One (2008) 2.02
Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios. Clin Chem (2009) 2.02
The Over-The-Scope Clip (OTSC) for the treatment of gastrointestinal bleeding, perforations, and fistulas. Surg Endosc (2011) 1.98
Magnetic resonance imaging of the body trunk using a single-slab, 3-dimensional, T2-weighted turbo-spin-echo sequence with high sampling efficiency (SPACE) for high spatial resolution imaging: initial clinical experiences. Invest Radiol (2005) 1.98
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res (2002) 1.95
Impact of age on the relationships of brown adipose tissue with sex and adiposity in humans. Diabetes (2010) 1.90
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother (2008) 1.88
Standardized assessment of whole body adipose tissue topography by MRI. J Magn Reson Imaging (2005) 1.85
Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr (2008) 1.78
A new wound-based severity score for diabetic foot ulcers: A prospective analysis of 1,000 patients. Diabetes Care (2006) 1.78
Processing of food pictures: influence of hunger, gender and calorie content. Brain Res (2010) 1.77
Identification of proliferative and mature β-cells in the islets of Langerhans. Nature (2016) 1.71
Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes. Radiology (2010) 1.71
Role of proton MR for the study of muscle lipid metabolism. NMR Biomed (2006) 1.65
Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res (2003) 1.65
High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care (2007) 1.64
Palmitate-induced interleukin-6 expression in human coronary artery endothelial cells. Diabetes (2004) 1.63
Primary malignant sarcomas of the heart and great vessels in adult patients--a single-center experience. Oncologist (2007) 1.63
FAIR true-FISP perfusion imaging of the kidneys. Magn Reson Med (2004) 1.63
Subjective feeling of appetite modulates brain activity: an fMRI study. Neuroimage (2006) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Impact of variation in the FTO gene on whole body fat distribution, ectopic fat, and weight loss. Obesity (Silver Spring) (2008) 1.59
Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insulin sensitivity. J Clin Endocrinol Metab (2003) 1.58